BTBP(SH:600161) Xin Lang Cai Jing·2025-10-24 09:37Core Viewpoint - TianTan Biological announced several key decisions made during the 26th meeting of the 9th Board of Directors, including the approval of the Q3 2025 report and structural changes within the company [1] Group 1: Financial Reporting - The Board approved the "Q3 2025 Report," indicating ongoing financial oversight and performance evaluation [1] Group 2: Organizational Changes - The decision was made to dissolve the Blood Source Management Center and establish a Blood Source Management Department and a Blood Source Management Region, reflecting a strategic restructuring [1] Group 3: Acquisitions - TianTan Wuhan agreed to acquire a 1% stake in Songzi Plasma Station for 22,266 yuan, which will result in the company holding 100% ownership of the station [1] Group 4: Management Authority - The Board authorized the General Manager's office to make decisions regarding pre-approval of economic activities, indicating a delegation of decision-making authority [1]